tbuckley/cabot-search huggingface dataset:
Patterns of care in renal cell carcinoma: Comparison of treatment duration for first-line sunitinib and pazopanib.
Authors: David Garofalo, Jim Montgomery, Jason Drenning, Bruce A. Feinberg
Journal: Journal of Clinical Oncology (2015)

e17615 Background: Renal cell carcinoma represents a dynamic therapeutic area with multiple classes of treatments and several new agents on the horizon with novel mechanisms of action. Understanding prescriber perceptions of efficacy and tolerability among leading treatments in a real-world population may inform current areas of unmet need and provide context for the adoption of new therapeutics. We conducted a retrospective analysis comparing the duration of therapy for sunitinib and pazopanib, the 2 leading systemic therapy options for newly diagnosed and relapsed patients with renal cell carcinoma. Methods: Using claims data (MORE2 Registry), patients with renal cell carcinoma who started and completed at least one line of treatment with sunitinib and/or pazopanib during the study period (January 2012 to February 2014) were identified by ICD9 code 189.0. Each patient’s treatment history was analyzed by line of therapy, defined as the line of therapy at disease progression or last regimen 90 days prior to date of data extraction (February 1, 2014). Patients were evaluated for duration of first-line therapy. Independent t-test analysis was performed to compare mean durations of first-line treatment with sunitinib versus pazopanib. Results: A total of 532 patients with renal cell carcinoma received a complete first-line treatment course with sunitinib (n = 361) or pazopanib (n = 171). Median duration of first-line therapy for sunitinib was 2.6 months (mean 4.0 months) compared to 3.0 months (mean 3.9 months) for pazopanib. There was no statistical difference in mean duration of therapy between the two groups of patients, P= .99. Conclusions: The duration of therapy was not statistically different for the two leading systemic agents used for the first-line treatment of renal cell carcinoma (sunitinib and pazopanib). Both agents had lower treatment duration than published trial results (range 4-8 months). Statistically equivalent and brief duration of treatment for both agents support toxicity and cost considerations as influential factors and suggest a continued unmet need in this therapeutic area.
Reactive Oxygen Species (ROS) Levels Define Functional Heterogeneity in Human Leukemia Stem Cells and Represent a Critical Parameter for Therapeutic Targeting
Authors: Eleni Lagadinou, Kevin Callahan, Sarah J Neering, ShanShan Pei, Mohammad Minhajuddin, Randall M Rossi, Valerie Grose, Cheryl Corbett, Marlene Balys, Paul Brookes, Craig T. Jordan
Journal: Blood (2011)
DIAGNÓSTICO MEDIANTE CAPSULOENDOSCOPIA DE LA ENTEROPATÍA DE LA HIPERTENSIÓN PORTAL
Authors: E Romero Romero, C Garfia Castillo, Á Masedo González, M Algara San Nicolas, C Piedracoba Cadahía, S Rodríguez Muñoz, P Martínez Montiel, G Castellano Tortajada
Journal: Endoscopy (2015)

Introducción: la enteropatía de la hipertensión portal (EHTP) es una entidad poco conocida en los pacientes con hipertensión portal (HTP), siendo considerada la capsuloendoscopia (CE) la herramienta diagnóstica de elección.
COMPARISON OF FALSE VERSUS TRUE ST ELEVATION MYOCARDIAL INFARCTION ACTIVATION RATES IN PATIENTS HAVING PRE-ACTIVATION POINT OF CARE TROPONIN LEVELS
Authors: Christina Dookhan, Abhijit Ghatak, Alejandro Mantero, Eduardo De Marchena, Ravi A. Patel, Cesar Mendoza, Alexandre Ferreira
Journal: Journal of the American College of Cardiology (2017)
Abstract 13451: Assessment of Diffuse Ventricular Fibrosis in Atrial Fibrillation Using Extracellular Volume Fraction: Initial Study
Authors: Song-Nan Li, Lei Zhao, Lu Wang, Hui Lin, Song-Nan Wen, Man Ning, Xiao-Hai Ma, Rong-Hui Yu, De-Yong Long, Ri-Bo Tang, Cai-Hua Sang, Chen-Xi Jiang, Nian Liu, Rong Bai, Xin Du, Jian-Zeng Dong, Zhan-Ming Fan, Chang-Sheng Ma
Journal: Circulation (2015)

Objectives: In atrial fibrillation (AF), diffuse myocardial fibrosis may be induced by arrhythmia or reflect pre-existing cardiomyopathy. The presence of concurrent AF and diffuse myocardial fibrosis has been associated with an increased risk of heart failure progression.Unlike focal fibrosis, diffuse myocardial fibrosis is not visualized on delayed enhancement magnetic resonance imaging (MRI), but can be quantified with ECV fraction. Hypothesis: The extracellular volume (ECV) fraction may provide new insights to evaluate diffuse myocardial fibrosis of the left ventricle (LV) in patients with AF. Methods: 78 subjects underwent MRI using a clinical 3 T scanner (Magnetom Verio, Siemens Healthcare): 25 persistent AF patients, 28 paroxysmal AF patients and 25 controls. Left-atrial volume was evaluated from MR cine imaging. A validated Look-Locker T1 Mapping Siemens prototype sequence was used to generate T1 maps as an index of diffuse myocardial fibrosis. The imaging parameters were: TE/TR = 1/295.33ms, FOV = 360mm, Slice Thickness = 8mm, image matrix = 192. 3 short axes of pre and post T1 maps were acquired as shown in Figure 1. ECV fraction was calculated from T1 maps acquired pre- and post-contrast calibrated by blood hematocrit. The ECV fraction was calculated as:ECV=(1-hematocrit)(1/(T1my post)-1/T1myopre)/(1/(T1blood post)-1/T1bloodpre) Results: AF patients had larger left atrial volume (persistent AF: 175.7±65.9ml; paroxysmal AF: 116.7±43.6ml) than controls (76.6±12.8ml) (paroxysmal vs. control: P&lt;0.01; persistent vs. control: P&lt;0.01). Mean ECV of persistent AF patients was 31.8±3.9% in the basal segments, 30.5±4.8% in the mid-cavity segments, 32.0±4.8% in the apical segments, paroxysmal AF patients were 29.2±3.6%, 28.2±3.5%, 31.5±4.6% respectively, which were higher than the controls (basal: 24.7±2.3%, mid-cavity: 25.9±2.4%, apical: 28.2±4.0%, all P&lt;0.05). Conclusion: ECV fraction could help to identify the diffuse LV fibrosis in patients with AF. The quantification could be a better solution for clinicians in diagnosing diffuse LV fibrosis.
Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma
Authors: Remy Dulery, Anthony Dohan, Maxime Barat, Mor Seny Gueye, Catherine Phan, Zora Marjanovic, Malek Aoudjhane, Elise Corre, Marie-Paule Lemonnier, Anne Vekhoff, Laurent Garderet, Ollivier Legrand, Paul Coppo, Philippe Soyer, Caroline Reinhold, Lionel Arrivé, Benoit Gallix, Mohamad Mohty
Journal: Blood (2016)
DIFFERING OUTCOMES OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTION AND THEIR IMPACT ON OVERALL NON-ST ELEVATION MYOCARDIAL INFARCTION MORTALITY RATES
Authors: Sameer Arora, Jacob Misenheimer, Paula D. Strassle, Arman Qamar, Matthew Cavender, Prashant Kaul
Journal: Journal of the American College of Cardiology (2017)
SAFETY AND EFFICACY OF USING PRESSURE WIRE WITH DOBUTAMIN INFUSION IN THEMOYNAMIC ASSESSMENT OF LOW FLOW LOW GRADIENT AORTIC STENOSIS
Authors: Zaher Fanari, Prasad Gunasekaran, Arslan Shaukat, Sumaya Hammami, Andrew J. Doorey, William Weintraub, Mark Wiley, Buddhadeb Dawn, Peter Tadros
Journal: Journal of the American College of Cardiology (2017)
THE VISCERAL ADIPOSITY INDEX PREDICTS CARDIOVASCULAR EVENTS BOTH IN CORONARY ARTERY DISEASE PATIENTS WITH AND IN CORONARY ARTERY DISEASE PATIENTS WITHOUT DIABETES
Authors: Alexander Vonbank, Christoph H. Saely, Philipp Rein, Andreas Leiherer, Daniela Zanolin, Heinz Drexel
Journal: Journal of the American College of Cardiology (2017)
PHYSICAL ACTIVITY LEVEL CHANGES AND THE OCCURRENCE OF NON-ALCOHOLIC FATTY-LIVER DISEASE: A PROSPECTIVE LONGITUDINAL FOLLOW UP STUDY
Authors: Marcio Sommer Bittencourt, Raphael M. Ritti-Dias, Aline Gerage, Gabriel G. Cucato, Raquel Conceicao, Raul Santos
Journal: Journal of the American College of Cardiology (2017)
Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.
Authors: Michael K.K. Wong, Eric Jonasch, Sumanta Kumar Pal, James E. Signorovitch, Peggy L. Lin, Zhimei Liu, Xufang Wang, Kenneth W. Culver, Jeffrey A. Scott, Daniel J. George, Nicholas J. Vogelzang
Journal: Journal of Clinical Oncology (2013)

e15500 Background: Current overall survival (OS) for metastatic renal cell carcinoma (mRCC) patients in clinical practice may differ from clinical trials. We aimed to identify and validate prognostic factors for OS in practice-based patients receiving 2nd-line everolimus (EVE), and to compare their OS vs. the RECORD-1 trial of EVE for mRCC. Methods: Two separate samples of oncologists/hematologists reviewed charts for patients initiating 2nd-line EVE between 2009 and 2011 following a 1st-line tyrosine kinase inhibitor (TKI). OS was defined as time from EVE initiation to death (censored at last follow-up). In the 1st sample of charts (the study sample), prognostic factors were identified via multivariable Cox proportional hazards models with stepwise selection. Prognostic factors considered included age, duration of mRCC and 1st-line treatment, metastatic sites, diabetes, histological subtype, ECOG and KPS score, and progression during 1st-line treatment. Model performance was assessed in the 2nd sample (the validation sample). Kaplan-Meier (KM) estimates for OS were compared between chart data and RECORD-1. Results: The study and validation samples included 220 and 97 patients, respectively. Significant prognostic factors were clear cell histology (hazard ratio (HR) = 2.9), KPS score &lt;80% (HR = 2.9), duration of mRCC &lt;1 year (HR = 2.7), progression on 1st-line TKI (HR = 2.2), and liver metastasis (HR = 1.9) (all P &lt;.05). In the validation sample, KM estimates for 1-year OS were 90% for patients with 0-2 risk factors, 62% for patients with 3 risk factors, and 20% for patients with 4-5 risk factors (log-rank P &lt;.001). OS estimates were consistent between both chart samples with 1-year OS probabilities of 67% and 68% and median OS of 19 and 23 months. In RECORD-1 1-year OS was 60% and median OS was 14.8 months (Motzer et al., 2010, Cancer). Conclusions: Prognostic factors for OS following 2nd-line EVE for mRCC in clinical practice were consistent with those previously identified in trial data. However, OS with 2nd-line EVE in clinical practice was longer than observed in trial data, and was not associated with type of 1st-line TKI.
<i>Staphylococcus aureus</i> colonization in atopic eczema and its association with filaggrin gene mutations
Authors: M.‐L. Clausen, S.M. Edslev, P.S. Andersen, K. Clemmensen, K.A. Krogfelt, T. Agner
Journal: British Journal of Dermatology (2017)

Atopic dermatitis (AD) is a prevalent disease with significant impact on physical health and quality of life. Staphylococcus aureus has been directly correlated to disease severity, and may also be a contributing causal factor in the pathogenesis of AD.The primary aim was to assess differences in S. aureus colonization in patients with AD with and without filaggrin gene mutations. The secondary aim was to assess disease severity in relation to S. aureus colonization. Exploratory analyses were performed to investigate S. aureus genetic lineages in relation to filaggrin gene (FLG) mutations and disease severity.Adult patients with AD (n = 101) were included in the study. Bacterial swabs were taken from lesional skin, nonlesional skin and the nose. Swabs positive for S. aureus were characterized by spa and the respective clonal complex (CC) type assigned. Patients were characterized with respect to disease severity (Scoring Atopic Dermatitis) and FLG mutations (n = 88). Fisher's exact test was used to analyse differences in S. aureus colonization in relation to FLG mutations.Of the 101 patients included, 74 (73%) were colonized with S. aureus. Of the colonized patients, 70 (95%) carried only one CC type in all three different sampling sites. In lesional skin, S. aureus was found in 24 of 31 patients with FLG mutations vs. 24 of 54 wild-type patients (P = 0·0004). Staphylococcus aureusCC1 clonal lineage was more prevalent in patients with FLG mutations (n = 10) than in wild-type patients (n = 2) (P = 0·003). No specific bacterial lineage was linked to disease severity.Increased S. aureus colonization in patients with AD with FLG mutations, and increased prevalence of CC1 in patients with FLG mutations, suggest that host-microbe interactions and clonal differences in S. aureus are important for colonization of AD skin.
DILATED MID-ASCENDING AORTA IN HYPERTROPHIC CARDIOMYOPATHY IS ASSOCIATED WITH DYNAMIC LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION AND NOT WITH GENETIC ABNORMALITIES
Authors: Lily Ann Walson, Afshan Husain, Mirza Mujadil Ahmad, Mirza Nubair Ahmad, Michelle Bush, Khawaja Afzal Ammar, Bijoy K. Khandheria, A. Jamil Tajik
Journal: Journal of the American College of Cardiology (2017)
Maintenance GM-CSF in patients with castration-resistant prostate cancer (CRPC) who maximized their response to chemotherapy
Authors: J. D. Bitran, K. Tolzien, T. M. Lestingi, C. Nabhan
Journal: Journal of Clinical Oncology (2009)

e16155 Background: There is no standard treatment for CRPC patients (pts) who completed chemotherapy. Time to progression (TTP) ranges from 3–6 months after stopping chemotherapy. GM-CSF (GM) is an immune-based growth factor with reported activity in CRPC. We hypothesized that GM maintenance in pts who have maximized their response to chemotherapy could delay TTP or time to next treatment (TNT). Methods: Eligible pts were those with CRPC who completed 10–12 cycles of docetaxel (D) or mitoxantrone (M) chemotherapy without progression; or those who maximized their response to chemotherapy before completing 10–12 cycles. Maximum response was defined as a &lt;10% change in PSA repeated on two occasions with stable disease (SD) radiographically. Enrolled pts received GM at 250 ug/m 2 subcutaneously for 14 days followed by 14-days of rest. GM was continued until disease progression. Primary end point was the clinical benefit defined as the sum of partial response (PR), complete response (CR) and SD. Secondary end points included toxicity, TTP, and TNT. Results: To date, 12 pts out of planned 20 have been enrolled (9 were on D and 3 on M). Median age was 78 (66–96). Median PSA at enrollment was 56.5 (0.1–566). Only 1 pt had a Gleason score &lt; 7. Median time from initial diagnosis to GM was 70 months. Median number of chemotherapy cycles prior to GM was 9 (6–12). Eight pts (66%) had visceral and bone disease. GM was well-tolerated with no drug-related grade 3 and/or 4 toxicities. Ten pts are evaluable (1 pt withdrew consent and another did not comply). Median GM cycles received so far was 3 (2–11). With a median follow up of 11 months (2–17), 3 pts demonstrated SD and 2 had PR for an overall clinical benefit of 50%. One pt remains on study at 7 months while the median response duration for the other 4 responding pts was 7 months. Four pts never received another treatment but the median TNT in other evaluable pts was 3 months. Conclusions: GM is safe, well tolerated, and has activity in CRPC after stopping chemotherapy. Combining chemotherapy with GM should be investigated in future studies. [Table: see text]
NPA7, A FIRST IN CLASS DUAL RECEPTOR ACTIVATOR WITH CARDIO-RENOPROTECTIVE PROPERTIES IN VIVO
Authors: Laura Meems, Ingrid Andersen, Brenda Huntley, Gail Harty, Yang Chen, Denise Heublein, Seethalakshmi (Seetha) Iyer, Shuchong Pan, Dan McCormick, Tomoko Ichiki, John Burnett
Journal: Journal of the American College of Cardiology (2017)
Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: H. J. Ross, C. M. Rudin, L. L. Hart, P. M. Swanson, M. U. Rarick, R. A. Figlin, A. D. Jacobs, D. M. Miller
Journal: Journal of Clinical Oncology (2004)

7039 Background: Docetaxel (Doc) remains the only FDA approved second line chemotherapy for NSCLC, but response rates and survival are low. Targeted therapies may hold more promise. NSCLC cells express a variety of tumor antigens, including the Lewis Y (Ley) antigen. SGN-15 is a novel antibody-drug conjugate that targets Ley, and delivers doxorubicin intracellularly. A multi-center randomized phase II study was conducted to evaluate the safety and efficacy of the combination of SGN-15/Doc as second or third line treatment for patients with advanced NSCLC who have progressed after platinum-based chemotherapy. Methods: In this 2:1 randomized study, 62 patients (pts) were randomly assigned to SGN-15 200 –350 mg/m2 + Doc 35 mg/m2 or Doc alone. A course of therapy was defined as 6 weekly doses within an 8 week period with response evaluation every 8 weeks. Primary endpoint was survival with secondary endpoints including response, toxicity and quality of life, Results: Median overall survival was 7.3 months for pts on the combination arm and 5.9 months on the Doc arm. Probability of survival at one year was 35% and 21% respectively. The most frequent treatment related AEs include nausea, vomiting, anorexia and fatigue. The most frequent grade 3–4 AEs were nausea and vomiting in both arms (15% and 13% respectively in the combination arm and 5% for both in the Doc arm). Quality-of-life measures, including FACT-L and FACT-Taxane, were not significantly different between arms; however, patients treated with SGN-15/Doc tended to do better in most measurements. Pharmacokinetics of SGN-15 were evaluated in a subset of patients by ELISA for the antibody portion and by HPLC-MS for the doxorubicin portion. The kinetics of SGN-15 elimination were consistent with previous single agent data, suggesting little influence of Doc on SGN-15 PK. Conclusion: Overall survival and tolerability data for the combination of SGN-15/Doc are encouraging and the regimen merits further study. Updated survival data will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Seattle Genetics Seattle Genetics Seattle Genetics Seattle Genetics
Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformations
Authors: Xia Wang, Wu-Lin Charng, Chun-An Chen, Jill A Rosenfeld, Aisha Al Shamsi, Lihadh Al-Gazali, Marianne McGuire, Nicholas Ah Mew, Georgianne L Arnold, Chunjing Qu, Yan Ding, Donna M Muzny, Richard A Gibbs, Christine M Eng, Magdalena Walkiewicz, Fan Xia, Sharon E Plon, James R Lupski, Christian P Schaaf, Yaping Yang
Journal: Nature Genetics (2017)
ASSOCIATION OF ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH ACUTE PULMONARY EMBOLISM AND CORONARY ARTERY CALCIFICATIONS VISUALIZED ON COMPUTED TOMOGRAPHY
Authors: Brett Carroll, Dominique DaBreo, Benedikt Heidinger, Stephanie Feldman, Donya Mohebali, Ian McCormick, Jason Matos, Warren Manning, Diana Litmanovich
Journal: Journal of the American College of Cardiology (2017)
RISK AND IMPACT OF DIABETES MELLITUS ON ISCHEMIC EVENTS IN FEMALES AND MALES AFTER PERCUTANEOUS CORONARY INTERVENTION
Authors: Serdar Farhan, Usman Baber, Jaya Chandrasekhar, Michela Faggioni, Pooja Vijay, Srushti Shah, Melissa Aquino, Samantha Sartori, Shrema Parikh, Sabato Sorrentino, Jason Kovacic, Srinivas Kesankurthy, Javed Suleman, Prakash Krishnan, Pedro Moreno, Birgit Vogel, Gennaro Giustino, George Dangas, Roxana Mehran, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2017)
EBV-positive lymphoma patients have a selective deficiency in EBV immunity
Authors: K. N. Heller, P. G. Steinherz, C. S. Portlock, C. Münz
Journal: Journal of Clinical Oncology (2007)

21032 Background: Epstein-Barr virus (EBV) asymptomatically establishes persistent infections in more than 90% of the adult population. However, due to effective immune control, only a minority of infected carriers develops spontaneous EBV-associated lymphomas. Since EBV nuclear antigen-1 (EBNA1) is the only protein expressed in all proliferating EBV infected cells we hypothesize that EBNA1 specific immune response is critical in preventing EBV-positive lymphomas. Methods: After informed consent, peripheral blood from healthy volunteers and lymphoma patients (prior to therapy- no evidence of cytopenia) were stimulated (ex vivo) with overlapping peptides covering the immunogenic EBNA1 (aa400–641) sequence. Frequency of EBNA1-specific T-cells were assessed by intracellular cytokine staining and flow cytometric proliferation assays. Cytokine pattern, surface marker phenotype and functional reactivity against EBV specific and control antigens were analyzed. Results: Patient and volunteer immune responses to control antigens and other viruses were assessed and statistically indistinguishable. EBNA1 specific CD4 + T cell responses were detected among 18 of 20 healthy carriers, and among 10 of 16 patients with EBV-negative lymphoma (relative to healthy volunteers p=0.145 via paired student T test). None of the patients with EBV-positive lymphomas (n=8) had a detectable EBNA1-specific CD4 + T-cell response (p&lt;0.003 relative to healthy volunteers and patients with EBV-negative lymphomas). Conclusions: Healthy volunteers and patients with EBV-negative lymphoma have statistically similar EBNA1-specific CD4 + T cell responses. Although patients with EBV-positive lymphoma have intact immune responses to common viruses and antigens, they selectively lack an EBNA1-specific CD4 + T cell response. An intact EBNA1 specific immune response among patients with EBV-negaitve lymphoma implies that lymphoma is not a cause of a selective immune deficiency. On the contrary, these findings suggest that EBNA1-specific CD4 + T cells are critical in the prevention of EBV mediated lymphomas, and a defect in EBNA1 specific immunity may leave EBV carriers suseptible to EBV-positive lymphomas. EBNA1- specific CD4 + T cell function may be a new target for therapies of EBV-associated malignancies. No significant financial relationships to disclose.
CORONARY ATHERECTOMY FOR TREATMENT OF CALCIFIED CORONARY ARTERY LESIONS IS ASSOCIATED WITH INCREASED PROCEDURAL SUCCESS AND LOWER PROCEDURAL COMPLICATION RATES: INSIGHTS FROM A NATIONAL VETERAN COHORT
Authors: Ehrin J. Armstrong, Maggie Stanislawski, Meg Plomondon, Subhash Banerjee, Stephen Waldo
Journal: Journal of the American College of Cardiology (2017)
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans
Authors: Daniel R. Carrasco, Tim Fenton, Kumar Sukhdeo, Marina Protopopova, Miriam Enos, Mingjian J. You, Dolores Di Vizio, Cristina Nogueira, Jayne Stommel, Geraldine S. Pinkus, Christopher Fletcher, Jason L. Hornick, Webster K. Cavenee, Frank B. Furnari, Ronald A. DePinho
Journal: Cancer Cell (2006)
Body Mass Index at 3 Weeks after Intensive Induction Regimen Is a Prognostic Factor for the Risk of Relapse and/or Failure in Patients with Acute Myeloid Leukemia
Authors: Lea Loriguet, Momar Diouf, Berengere Gruson, Delphine Lebon, Amandine Charbonnier, Dorothée Laine, Pierre Morel, Jean Pierre Marolleau
Journal: Blood (2016)